Transmedics Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.8%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$741.7Mnext fiscal year
FY EPS (est.)
$1.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly173.9MTarget: 727000000 to 757000000
Owned Aircraft Fleet Size Quarterly22.0
National OCS Program (NOP) Flight Mission Coverage Quarterly0.8Target: Maintain high coverage
Watch Items
- U.S. Transplant Modernization Act Impact
- ENHANCE Heart and DENOVO Lung Clinical Trial EnrollmentAction: Accelerate the deployment of the CHOPS device to mitigate enrollment challenges
- Operating Margin CompressionAction: Implement cost-discipline measures across SG&A and optimize aviation logistics utilization
Research as of 19 Jun 2026